In its third precedential patent opinion this week, the U.S. Court of Appeals for the Federal Circuit (CAFC) earlier today upheld a Patent Trial and Appeal Board (PTAB) decision finding that Mylan Pharmaceuticals, Inc. failed to show that certain claims of Merck Sharp & Dohme Corp.’s patent for a Type 2 Diabetes treatment were anticipated or would have been obvious over the cited prior art. Judge Lourie authored the opinion.
Recent Posts
- Clause 8: Ed Murgitroyd on Disrupting IP Services and Leading a Publicly Traded IP Law Firm
- USPTO Names New Advisory Board Members on Heels of PPAC Report Forecasting Downward Trend in Finances
- APPLE JAZZ Trademark Fight Continues at CAFC
- Straight to the Prompt: IP Lawyers Must Develop AI Skills NOW
- This Week in Washington IP: Evaluating the U.S.’s Role in IP Leadership, CHIPS Act Successes and Semiconductor Production, and the White House Policy on AI